Skip to main content
. Author manuscript; available in PMC: 2014 Jan 9.
Published in final edited form as: Exp Clin Psychopharmacol. 2013 Feb 18;21(2):10.1037/a0031692. doi: 10.1037/a0031692

Table 2.

All participant and observer rated, motor/cognitive, and physiological outcome measures (peak measures for those for which timecourse was assessed) for which either 1) a significant planned comparison effect was found for at least 1 dose of either drug compared to placebo, or 2) a significant effect was found in the planned contrast comparing the least-squares adjusted mean of the highest 3 doses between each drug.

Measure Drug vs placebo a Drug vs drug b

GHB vs PL ETOH vs PL GHB vs ETOH
Participant & Observer Rated
 Alertness/sleepiness VAS (SEQ) + + NS
 Drug Effect (SEQ) + + NS
 Arousing (SEQ) + + NS
 Depressant (SEQ) + + NS
 Like (SEQ) + + NS
 Good Effect (SEQ) + + NS
 Bad Effect (SEQ) + + NS
 Headache (SEQ) NS + ETOH > GHB
 Confused (SEQ) + + NS
 Sleepy (SEQ) + + NS
 Blurred Vision (SEQ) + + GHB > ETOH
 Limp (SEQ) + + NS
 Lightheaded (SEQ) + + GHB > ETOH
 Queasy (SEQ) + + NS
 Fatigued (SEQ) + + NS
 Unsteady (SEQ) + + NS
 Hot (SEQ) + + NS
 Diff. Concentrating (SEQ) + + NS
 Slurred Speech (SEQ) + + NS
 Mentally slow (SEQ) + + NS
 Heavy limbs (SEQ) + + NS
 Tired (SEQ) + + NS
 Easy going (SEQ) + + NS
 Forgetful (SEQ) + + NS
 Talkative (SEQ) + + NS
 Excited (SEQ) NS + NS
 Comfortable (SEQ) + NS GHB > ETOH
 Relaxed (SEQ) + NS NS
 Nervous (SEQ) + + NS
 Numbness (SEQ) + + NS
 Restless (SEQ) NS + NS
 Dry Mouth (SEQ) + + NS
 Shaky (SEQ) + + NS
 Irritable (SEQ) NS + NS
 Drug Effect (DEQ) + + NS
 Liking (DEQ) + + NS
 PEQ (DEQ) + + NS
 Disliking (DEQ) NS + NS
 PCAG (ARCI) + + GHB > ETOH
 Benzedrine (ARCI) GHB > ETOH
 Amphetamine (ARCI) NS + NS
 MBG (ARCI) NS + NS
 LSD (ARCI) + + GHB > ETOH
 Euphoria (ARCI) + + NS
 Sedation (ARCI) + + GHB > ETOH
 Drug effect (NDQ) + + NS
 Liking (NDQ) + + GHB > ETOH
 Disliking (NDQ) NS + NS
 Good effects (NDQ) + + GHB > ETOH
 Bad effects (NDQ) + + NS
 Take again (NDQ) + + GHB > ETOH
 DE worth (NDQ) + + NS
 Willing to pay (NDQ) + + NS
 Hangover rating NS + ETOH > GHB
 Crossover point (MCP) NS GHB > ETOH
 DSST Performance Estimate NS NS
 Cir Lights Performance Estimate NS NS
 Word Recall Performance Estimate NS
 Level of Alertness (Observer) GHB > ETOH
 Relaxed (Observer) + + NS
 Speech (Observer) + + NS
 Confused (Observer) + + NS
 Stimulated (Observer) + + NS
 Drug effect (Observer) + + NS
 Posture (Observer) + + NS
 Sleep Time (Observer) + + NS
 Total Sleep Time (Observer) + + NS
Motor/Cognitive
 Immediate trials (Digit recall) NS
 Word Recall NS NS
 Word Recognition d′ ETOH > GHB
 DSST NS
 Balance NS
 Circular lights NS
Physiological
 Systolic + + NS
 Diastolic NS
 Pulse + + ETOH > GHB
a

These two columns show the results of planned comparisons of placebo with 12, 24, 48, and 120 g/70 kg ETOH and 1, 2, 4, 6, 8, and 10 g/70 kg GHB. Symbol (+ or −) indicates that at least one dose of the drug was significantly different from placebo (p ≤ .05); symbol (+ or −) also indicates the direction of the drug effect relative to placebo. For the alertness/sleepiness VAS, higher scores denote sleepiness. For performance estimates, + indicates that participants underestimated performance relative to actual performance more so for the drug than placebo. NS indicates no dose of that drug was different from placebo.

b

This column shows the results of a planned contrast comparing the mean of the top 3 doses of GHB (6, 8, 10 g/70kg) to the mean of the top 3 doses of ETOH (72, 96, 120 g/70kg). The drug to the left of the symbol (>) produced a significantly greater effect. NS indicates that the effects produced by the doses of the two drugs were not significantly different.